Treatment outcomes after initiating buprenorphine/naloxone or methadone for opioid use disorder among First Nation Peoples in Ontario, Canada

An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada

10.1016/j.dialog.2024.100190 · doi-reference

Management of opioid use disorder: 2024 update to the national clinical practice guideline

10.1503/cmaj.241173 · doi-reference

Harnessing the healing power of the land: Culturally appropriate treatments for Indigenous persons with a substance use disorder

10.3389/fpsyt.2026.1796719 · doi-reference

Unlocking First Nations health information through data linkage

10.23889/ijpds.v3i1.450 · doi-reference

Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: A retrospective cohort study of US veterans

10.1007/s11606-021-06969-1 · doi-reference

One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission

10.1016/j.jsat.2020.108031 · doi-reference

Unmasking population undercounts, health inequities, and health service access barriers across Indigenous populations in urban Ontario

10.17269/s41997-024-00957-8 · doi-reference

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

10.1097/01.mlr.0000182534.19832.83 · doi-reference

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: An integrative review

10.1186/s13011-022-00463-5 · doi-reference

Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder

10.1001/jama.2024.16954 · doi-reference

Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: Protocol for a population-based target trial emulation

10.1136/bmjopen-2024-098318 · doi-reference

Community-led recovery from the opioid crisis through culturally-based programs and community-based data governance

10.18584/iipj.2022.13.2.13792 · doi-reference

Identifying diabetes cases from administrative data: A population-based validation study

10.1186/s12913-018-3148-0 · doi-reference

Duration of methadone and buprenorphine-naloxone treatment

10.1001/jamanetworkopen.2025.18389 · doi-reference

Deficit-based indigenous health research and the stereotyping of indigenous peoples

10.7202/1065690ar · doi-reference

Consolidated criteria for strengthening reporting of health research involving indigenous peoples: The CONSIDER statement

10.1186/s12874-019-0815-8 · doi-reference

Retention in opioid agonist therapy among first nations people

10.1001/jamanetworkopen.2025.18452 · doi-reference

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: A population-based propensity-score matched cohort study

10.1111/add.15862 · doi-reference

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis

10.1016/j.drugalcdep.2022.109459 · doi-reference

The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine

10.1111/add.15115 · doi-reference

Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario: A population-based retrospective cohort study

10.1097/cxa.0000000000000192 · doi-reference

Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)

10.1111/j.1360-0443.2004.00654.x · doi-reference

Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone

10.1503/cmaj.090784 · doi-reference

Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies

10.1016/s2215-0366(23)00095-0 · doi-reference

The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis

10.1097/yco.0000000000000717 · doi-reference

Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence

10.1159/000520185 · doi-reference

Management of opioid use disorders: A national clinical practice guideline

10.1503/cmaj.170958 · doi-reference

The intergenerational effects of Indian Residential Schools: Implications for the concept of historical trauma

10.1177/1363461513503380 · doi-reference

The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement

10.1371/journal.pmed.1001885 · doi-reference

The opioid crisis in Canada: A national perspective

10.24095/hpcdp.38.6.02 · doi-reference

An introduction to propensity score methods for reducing the effects of confounding in observational studies

10.1080/00273171.2011.568786 · doi-reference

Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research

10.1080/03610910902859574 · doi-reference

Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection

10.1371/journal.pone.0021748 · doi-reference

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: A mixed methods systematic review

10.1186/s13011-023-00564-9 · doi-reference